Comprehensive genomic characterization of squamous cell lung cancers
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no molecularly targeted agents have been specifically developed for its treatment. As part of The Cancer Genome Atlas, here we profile 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations. We show that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour. We find statistically recurrent mutations in 11 genes, including mutation of TP53 in nearly all specimens. Previously unreported loss-of-function mutations are seen in the HLA-A class I major histocompatibility gene. Significantly altered pathways included NFE2L2 and KEAP1 in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A and RB1 in 72% of tumours. We identified a potential therapeutic target in most tumours, offering new avenues of investigation for the treatment of squamous cell lung cancers. Comprehensive analyses of 178 lung squamous cell carcinomas by The Cancer Genome Atlas project show that the tumour type is characterized by complex genomic alterations, with statistically recurrent mutations in 11 genes, including TP53 in nearly all samples; a potential therapeutic target is identified in most of the samples studied. The Cancer Genome Atlas consortium has analysed 178 lung squamous cell carcinomas, a common type of lung cancer for which comprehensive genomic analyses have not previously been available. The researchers report that this tumour type is characterized by complex genomic alterations, with recurrent mutations in 18 genes, including TP53 in nearly all samples. They also report frequent mutations in squamous differentiation genes. Collectively, these analyses identify potential therapeutic targets worthy of further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite many additional doublings in culture, this point mutational frequency (2.16 per Mb) is on the lower end of frequencies observed across different cancer genomes22.”
From The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line (2013) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“Genomic characterization of squamous cell lung cancers showed significant alterations in the Nrf2 pathway in 34% of all tumour specimens examined [175].”
From Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease (2022) · cites this paper as [175]
In the citing paper
“Combined PI3K and CDK4/6 inhibition may also be of substantial interest in squamous cell NSCLC and head and neck cancer, where amplification of both CCND1 and PIK3CA are common events (117, 118), as well as in pancreatic cancer, where genetically engineered mouse models have suggested the importance of the PI3K pathway downstream from activated KRAS (119).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [118]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“2); (2) confirmation of the altered allele in RNA sequencing; and (3) the mutation assessor score(40).”
BackgroundPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationMermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Cited by
Items 301–400 of 1,021
Chen, Y.-P., Zhang, Y., Lv, J.-W., Li, Y.-Q., Wang, Y.-Q., He, Q.-M., Yang, X.-J., Sun, Y., Mao, Y.-P., Yun, J.-P., et al. (2017) · Theranostics · doi:10.7150/thno.21471 · Cited by 232
Wang, C., Yu, Q., Song, T., Wang, Z., Song, L., Yang, Y., Shao, J., Li, J., Ni, Y., Chao, N., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01130-8 · Cited by 231
Clinical next‐generation sequencing in patients with non–small cell lung cancer
Hagemann, I. S., Devarakonda, S., Lockwood, C. M., Spencer, D. H., Guebert, K., Bredemeyer, A. J., Al‐Kateb, H., Nguyen, T. T., Duncavage, E. J., Cottrell, C. E., et al. (2015) · Cancer · doi:10.1002/cncr.29089 · Cited by 230
Labbé, C., Cabanero, M., Korpanty, G. J., Tomasini, P., Doherty, M. K., Mascaux, C., Jao, K., Pitcher, B., Wang, R., Pintilie, M., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.014 · Cited by 230
Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
Sosa Iglesias, V., Giuranno, L., Dubois, L. J., Theys, J., & Vooijs, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00267 · Cited by 229
Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
Pietanza, M. C., Byers, L. A., Minna, J. D., & Rudin, C. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2958 · Cited by 228
A pan-cancer analysis of synonymous mutations
Sharma, Y., Miladi, M., Dukare, S., Boulay, K., Caudron-Herger, M., Groß, M., Backofen, R., & Diederichs, S. (2019) · Nature Communications · doi:10.1038/s41467-019-10489-2 · Cited by 225
Mutational signatures are jointly shaped by DNA damage and repair
Volkova, N. V., Meier, B., González-Huici, V., Bertolini, S., Gonzalez, S., Vöhringer, H., Abascal, F., Martincorena, I., Campbell, P. J., Gartner, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15912-7 · Cited by 228
Inferring gene expression from cell-free DNA fragmentation profiles
Esfahani, M. S., Hamilton, E. G., Mehrmohamadi, M., Nabet, B. Y., Alig, S. K., King, D. A., Steen, C. B., Macaulay, C. W., Schultz, A., Nesselbush, M. C., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01222-4 · Cited by 221
Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression
Jiang, Y., Jiang, Y.-Y., Xie, J.-J., Mayakonda, A., Hazawa, M., Chen, L., Xiao, J.-F., Li, C.-Q., Huang, M.-L., Ding, L.-W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06081-9 · Cited by 227
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer
Socinski, M. A., Obasaju, C., Gandara, D., Hirsch, F. R., Bonomi, P., Bunn, P. A., Kim, E. S., Langer, C. J., Natale, R. B., Novello, S., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.111 · Cited by 227
Papachristofilou, A., Hipp, M. M., Klinkhardt, U., Früh, M., Sebastian, M., Weiss, C., Pless, M., Cathomas, R., Hilbe, W., Pall, G., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0520-5 · Cited by 227
The crucial role of multiomic approach in cancer research and clinically relevant outcomes
Lu, M., & Zhan, X. (2018) · EPMA Journal · doi:10.1007/s13167-018-0128-8 · Cited by 224
Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer
White, N. M., Cabanski, C. R., Silva-Fisher, J. M., Dang, H. X., Govindan, R., & Maher, C. A. (2014) · Genome Biology · doi:10.1186/preaccept-8565849481270705 · Cited by 225
Roles of Nrf2 in cell proliferation and differentiation
Murakami, S., & Motohashi, H. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.030 · Cited by 225
Telonis, A. G., Magee, R., Loher, P., Chervoneva, I., Londin, E., & Rigoutsos, I. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx082 · Cited by 224
Linehan, W. M., & Rouault, T. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0304 · Cited by 223
Shu, Y., Wu, X., Tong, X., Wang, X., Chang, Z., Mao, Y., Chen, X., Sun, J., Wang, Z., Hong, Z., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00520-1 · Cited by 223
Recent Clinical Advances in Lung Cancer Management
Johnson, D. H., Schiller, J. H., & Bunn, P. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1228 · Cited by 221
The NF1 gene in tumor syndromes and melanoma
Kiuru, M., & Busam, K. J. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2016.142 · Cited by 217
Molecular pathways and therapeutic targets in lung cancer
Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., & Salgia, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1891 · Cited by 220
Raphael, B. J., Dobson, J. R., Oesper, L., & Vandin, F. (2014) · Genome Medicine · doi:10.1186/gm524 · Cited by 218
Tight junction proteins: From barrier to tumorigenesis
Runkle, E. A., & Mu, D. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.038 · Cited by 215
Rahman, M., Jackson, L. K., Johnson, W. E., Li, D. Y., Bild, A. H., & Piccolo, S. R. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv377 · Cited by 215
Best practices for bioinformatic characterization of neoantigens for clinical utility
Richters, M. M., Xia, H., Campbell, K. M., Gillanders, W. E., Griffith, O. L., & Griffith, M. (2019) · Genome Medicine · doi:10.1186/s13073-019-0666-2 · Cited by 214
TP53 gain-of-function mutation promotes inflammation in glioblastoma
Ham, S. W., Jeon, H.-Y., Jin, X., Kim, E.-J., Kim, J.-K., Shin, Y. J., Lee, Y., Kim, S. H., Lee, S. Y., Seo, S., et al. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0126-3 · Cited by 213
Self-citationBecht, E., Giraldo, N. A., Germain, C., de Reyniès, A., Laurent-Puig, P., Zucman-Rossi, J., Dieu-Nosjean, M.-C., Sautès-Fridman, C., & Fridman, W. H. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.002 · Cited by 213
Nanomaterials for Cancer Precision Medicine
Wang, Y., Sun, S., Zhang, Z., & Shi, D. (2018) · Advanced Materials · doi:10.1002/adma.201705660 · Cited by 212
Squamous cell lung cancer: Current landscape and future therapeutic options
Lau, S. C. M., Pan, Y., Velcheti, V., & Wong, K. K. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.018 · Cited by 207
High-throughput phenotyping of lung cancer somatic mutations
Berger, A. H., Brooks, A. N., Wu, X., Shrestha, Y., Chouinard, C., Piccioni, F., Bagul, M., Kamburov, A., Imielinski, M., Hogstrom, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.022 · Cited by 192
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium
Pillai, R. N., Behera, M., Berry, L. D., Rossi, M. R., Kris, M. G., Johnson, B. E., Bunn, P. A., Ramalingam, S. S., & Khuri, F. R. (2017) · Cancer · doi:10.1002/cncr.30869 · Cited by 209
Koneva, L. A., Zhang, Y., Virani, S., Hall, P. B., McHugh, J. B., Chepeha, D. B., Wolf, G. T., Carey, T. E., Rozek, L. S., & Sartor, M. A. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0153 · Cited by 209
Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model
Zhang, Z., Shiratsuchi, H., Lin, J., Chen, G., Reddy, R. M., Azizi, E., Fouladdel, S., Chang, A. C., Lin, L., Jiang, H., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2592 · Cited by 207
Zhang, X.-C., Wang, J., Shao, G.-G., Wang, Q., Qu, X., Wang, B., Moy, C., Fan, Y., Albertyn, Z., Huang, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09762-1 · Cited by 209
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
Ho, A. L., Brana, I., Haddad, R., Bauman, J., Bible, K., Oosting, S., Wong, D. J., Ahn, M.-J., Boni, V., Even, C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02903 · Cited by 208
Radiomics and artificial intelligence for precision medicine in lung cancer treatment
Chen, M., Copley, S. J., Viola, P., Lu, H., & Aboagye, E. O. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.05.004 · Cited by 206
Claudin-low bladder tumors are immune infiltrated and actively immune suppressed
Kardos, J., Chai, S., Mose, L. E., Selitsky, S. R., Krishnan, B., Saito, R., Iglesia, M. D., Milowsky, M. I., Parker, J. S., Kim, W. Y., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85902 · Cited by 207
La Fleur, L., Falk-Sörqvist, E., Smeds, P., Berglund, A., Sundström, M., Mattsson, J. S., Brandén, E., Koyi, H., Isaksson, J., Brunnström, H., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.003 · Cited by 207
Fang, W., Ma, Y., Yin, J. C., Hong, S., Zhou, H., Wang, A., Wang, F., Bao, H., Wu, X., Yang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0585 · Cited by 207
Drilon, A., Rekhtman, N., Ladanyi, M., & Paik, P. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70291-7 · Cited by 204
Precision Management of Advanced Non–Small Cell Lung Cancer
Yang, C.-Y., Yang, J. C.-H., & Yang, P.-C. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051718-013524 · Cited by 203
Teschendorff, A. E., Yang, Z., Wong, A., Pipinikas, C. P., Jiao, Y., Jones, A., Anjum, S., Hardy, R., Salvesen, H. B., Thirlwell, C., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1053 · Cited by 204
Takagi, S., Sato, S., Oh-hara, T., Takami, M., Koike, S., Mishima, Y., Hatake, K., & Fujita, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073609 · Cited by 204
Genomic–transcriptomic evolution in lung cancer and metastasis
Martínez-Ruiz, C., Black, J. R. M., Puttick, C., Hill, M. S., Demeulemeester, J., Larose Cadieux, E., Thol, K., Jones, T. P., Veeriah, S., Naceur-Lombardelli, C., et al. (2023) · Nature · doi:10.1038/s41586-023-05706-4 · Cited by 201
Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients
Kim, Y., Hammerman, P. S., Kim, J., Yoon, J.-A., Lee, Y., Sun, J.-M., Wilkerson, M. D., Pedamallu, C. S., Cibulskis, K., Yoo, Y. K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.8556 · Cited by 202
Activation of the NOTCH Pathway in Head and Neck Cancer
Sun, W., Gaykalova, D. A., Ochs, M. F., Mambo, E., Arnaoutakis, D., Liu, Y., Loyo, M., Agrawal, N., Howard, J., Li, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1259 · Cited by 200
Wang, P., Ning, S., Zhang, Y., Li, R., Ye, J., Zhao, Z., Zhi, H., Wang, T., Guo, Z., & Li, X. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv233 · Cited by 201
Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications
Marino, F. Z., Bianco, R., Accardo, M., Ronchi, A., Cozzolino, I., Morgillo, F., Rossi, G., & Franco, R. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.34739 · Cited by 200
Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201
Immune microenvironment composition in non‐small cell lung cancer and its association with survival
Tamminga, M., Hiltermann, T. J. N., Schuuring, E., Timens, W., Fehrmann, R. S., & Groen, H. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1142 · Cited by 201
Umemura, S., Mimaki, S., Makinoshima, H., Tada, S., Ishii, G., Ohmatsu, H., Niho, S., Yoh, K., Matsumoto, S., Takahashi, A., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000250 · Cited by 200
Characterizing DNA methylation alterations from The Cancer Genome Atlas
Weisenberger, D. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69740 · Cited by 200
“Overall, LUSCs displayed increased rates of DNA sequence alterations compared with other tumor types.”
InfluentialRecurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers
Goldstein, L. D., Lee, J., Gnad, F., Klijn, C., Schaub, A., Reeder, J., Daemen, A., Bakalarski, C. E., Holcomb, T., Shames, D. S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.010 · Cited by 200
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B., Gu, Y., Hare, B., Johnson, M. A., Li, H., Milton, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2158 · Cited by 199
Inferring regulatory element landscapes and transcription factor networks from cancer methylomes
Yao, L., Shen, H., Laird, P. W., Farnham, P. J., & Berman, B. P. (2015) · Genome Biology · doi:10.1186/s13059-015-0668-3 · Cited by 198
Comprehensive characterization of lncRNA-mRNA related ceRNA network across 12 major cancers
Zhang, Y., Xu, Y., Feng, L., Li, F., Sun, Z., Wu, T., Shi, X., Li, J., & Li, X. (2016) · Oncotarget · doi:10.18632/oncotarget.11637 · Cited by 198
Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing
Euskirchen, P., Bielle, F., Labreche, K., Kloosterman, W. P., Rosenberg, S., Daniau, M., Schmitt, C., Masliah-Planchon, J., Bourdeaut, F., Dehais, C., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1743-5 · Cited by 196
Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
Judd, J., Abdel Karim, N., Khan, H., Naqash, A. R., Baca, Y., Xiu, J., VanderWalde, A. M., Mamdani, H., Raez, L. E., Nagasaka, M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0201 · Cited by 194
SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K/AKT/SOX2 axis and beyond
Schaefer, T., & Lengerke, C. (2020) · Oncogene · doi:10.1038/s41388-019-0997-x · Cited by 197
Garrido-Martin, E. M., Mellows, T. W. P., Clarke, J., Ganesan, A.-P., Wood, O., Cazaly, A., Seumois, G., Chee, S. J., Alzetani, A., King, E. V., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000778 · Cited by 196
A Cellular Mechanism to Detect and Alleviate Reductive Stress
Manford, A. G., Rodríguez-Pérez, F., Shih, K. Y., Shi, Z., Berdan, C. A., Choe, M., Titov, D. V., Nomura, D. K., & Rape, M. (2020) · Cell · doi:10.1016/j.cell.2020.08.034 · Cited by 191
Cells of origin of lung cancers: lessons from mouse studies
Ferone, G., Lee, M. C., Sage, J., & Berns, A. (2020) · Genes & Development · doi:10.1101/gad.338228.120 · Cited by 196
Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung
Miyoshi, T., Umemura, S., Matsumura, Y., Mimaki, S., Tada, S., Makinoshima, H., Ishii, G., Udagawa, H., Matsumoto, S., Yoh, K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0355 · Cited by 195
Santoni-Rugiu, E., Melchior, L. C., Urbanska, E. M., Jakobsen, J. N., de Stricker, K., Grauslund, M., & Sørensen, J. B. (2019) · Cancers · doi:10.3390/cancers11070923 · Cited by 194
Molecular basis for the disruption of Keap1–Nrf2 interaction via Hinge & Latch mechanism
Horie, Y., Suzuki, T., Inoue, J., Iso, T., Wells, G., Moore, T. W., Mizushima, T., Dinkova-Kostova, A. T., Kasai, T., Kamei, T., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02100-6 · Cited by 189
Genomic heterogeneity of multiple synchronous lung cancer
Liu, Y., Zhang, J., Li, L., Yin, G., Zhang, J., Zheng, S., Cheung, H., Wu, N., Lu, N., Mao, X., et al. (2016) · Nature Communications · doi:10.1038/ncomms13200 · Cited by 194
Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma
Han, X., Li, F., Fang, Z., Gao, Y., Li, F., Fang, R., Yao, S., Sun, Y., Li, L., Zhang, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms4261 · Cited by 193
Non‐small cell lung cancer is characterized by dramatic changes in phospholipid profiles
Marien, E., Meister, M., Muley, T., Fieuws, S., Bordel, S., Derua, R., Spraggins, J., Van de Plas, R., Dehairs, J., Wouters, J., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29517 · Cited by 193
Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers
Salmaninejad, A., Zamani, M. R., Pourvahedi, M., Golchehre, Z., Hosseini Bereshneh, A., & Rezaei, N. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1197241 · Cited by 193
Role and regulation of autophagy in cancer
Rakesh, R., PriyaDharshini, L. C., Sakthivel, K. M., & Rasmi, R. R. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166400 · Cited by 192
The genomic landscape of schwannoma
Agnihotri, S., Jalali, S., Wilson, M. R., Danesh, A., Li, M., Klironomos, G., Krieger, J. R., Mansouri, A., Khan, O., Mamatjan, Y., et al. (2016) · Nature Genetics · doi:10.1038/ng.3688 · Cited by 189
Vaz, M., Hwang, S. Y., Kagiampakis, I., Phallen, J., Patil, A., O'Hagan, H. M., Murphy, L., Zahnow, C. A., Gabrielson, E., Velculescu, V. E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.006 · Cited by 191
Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01355-5 · Cited by 188
PDXNET Consortium, Woo, X. Y., EurOPDX Consortium, Giordano, J., Srivastava, A., Zhao, Z.-M., Lloyd, M. W., de Bruijn, R., Suh, Y.-S., Patidar, R., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00750-6 · Cited by 190
The NF1 gene revisited - from bench to bedside
Yap, Y.-S., McPherson, J. R., Ong, C.-K., Rozen, S. G., Teh, B.-T., Lee, A. S. G., & Callen, D. F. (2014) · Oncotarget · doi:10.18632/oncotarget.2194 · Cited by 189
Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma
Nassar, D., Latil, M., Boeckx, B., Lambrechts, D., & Blanpain, C. (2015) · Nature Medicine · doi:10.1038/nm.3878 · Cited by 189
Takahashi, N., Cho, P., Selfors, L. M., Kuiken, H. J., Kaul, R., Fujiwara, T., Harris, I. S., Zhang, T., Gygi, S. P., & Brugge, J. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.010 · Cited by 189
Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer
Yu, J., Wu, W. K. K., Li, X., He, J., Li, X.-X., Ng, S. S. M., Yu, C., Gao, Z., Yang, J., Li, M., et al. (2015) · Gut · doi:10.1136/gutjnl-2013-306620 · Cited by 188
NRF2: KEAPing Tumors Protected
Pillai, R., Hayashi, M., Zavitsanou, A.-M., & Papagiannakopoulos, T. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0922 · Cited by 184
Rodon, J., Braña, I., Siu, L. L., De Jonge, M. J., Homji, N., Mills, D., Di Tomaso, E., Sarr, C., Trandafir, L., Massacesi, C., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0082-9 · Cited by 186
Lung Cancer in the Era of Precision Medicine
Politi, K., & Herbst, R. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2748 · Cited by 187
NRF2 Activation in Cancer: From DNA to Protein
Cloer, E. W., Goldfarb, D., Schrank, T. P., Weissman, B. E., & Major, M. B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2723 · Cited by 184
Strong, M. J., Xu, G., Morici, L., Splinter Bon-Durant, S., Baddoo, M., Lin, Z., Fewell, C., Taylor, C. M., & Flemington, E. K. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004437 · Cited by 186
SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas
Watanabe, H., Ma, Q., Peng, S., Adelmant, G., Swain, D., Song, W., Fox, C., Francis, J. M., Pedamallu, C. S., DeLuca, D. S., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71545 · Cited by 184
ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
Phillips, A. C., Boghaert, E. R., Vaidya, K. S., Mitten, M. J., Norvell, S., Falls, H. D., DeVries, P. J., Cheng, D., Meulbroek, J. A., Buchanan, F. G., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0901 · Cited by 180
Novel therapeutic targets on the horizon for lung cancer
Tan, W.-L., Jain, A., Takano, A., Newell, E. W., Iyer, N. G., Lim, W.-T., Tan, E.-H., Zhai, W., Hillmer, A. M., Tam, W.-L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30123-1 · Cited by 184
Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer
Siegel, M. B., He, X., Hoadley, K. A., Hoyle, A., Pearce, J. B., Garrett, A. L., Kumar, S., Moylan, V. J., Brady, C. M., Van Swearingen, A. E. D., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96153 · Cited by 183
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma
Momcilovic, M., Bailey, S. T., Lee, J. T., Fishbein, M. C., Braas, D., Go, J., Graeber, T. G., Parlati, F., Demo, S., Li, R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.002 · Cited by 181
Decoding the tumor microenvironment with spatial technologies
Walsh, L. A., & Quail, D. F. (2023) · Nature Immunology · doi:10.1038/s41590-023-01678-9 · Cited by 180
Clinicopathologic Features of Advanced Squamous NSCLC
Socinski, M. A., Obasaju, C., Gandara, D., Hirsch, F. R., Bonomi, P., Bunn, P., Kim, E. S., Langer, C. J., Natale, R. B., Novello, S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.024 · Cited by 180
Han, L., Yuan, Y., Zheng, S., Yang, Y., Li, J., Edgerton, M. E., Diao, L., Xu, Y., Verhaak, R. G. W., & Liang, H. (2014) · Nature Communications · doi:10.1038/ncomms4963 · Cited by 178
A genetic basis for the variation in the vulnerability of cancer to DNA damage
Yard, B. D., Adams, D. J., Chie, E. K., Tamayo, P., Battaglia, J. S., Gopal, P., Rogacki, K., Pearson, B. E., Phillips, J., Raymond, D. P., et al. (2016) · Nature Communications · doi:10.1038/ncomms11428 · Cited by 175
Ganapathy, V., Manyanga, J., Brame, L., McGuire, D., Sadhasivam, B., Floyd, E., Rubenstein, D. A., Ramachandran, I., Wagener, T., & Queimado, L. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177780 · Cited by 178
A novel approach for data integration and disease subtyping
Nguyen, T., Tagett, R., Diaz, D., & Draghici, S. (2017) · Genome Research · doi:10.1101/gr.215129.116 · Cited by 177
Sebestyén, E., Zawisza, M., & Eyras, E. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1392 · Cited by 177
Pan-cancer patterns of DNA methylation
Witte, T., Plass, C., & Gerhauser, C. (2014) · Genome Medicine · doi:10.1186/s13073-014-0066-6 · Cited by 175
Next generation sequencing‐based gene panel tests for the management of solid tumors
Nagahashi, M., Shimada, Y., Ichikawa, H., Kameyama, H., Takabe, K., Okuda, S., & Wakai, T. (2019) · Cancer Science · doi:10.1111/cas.13837 · Cited by 177
Vignot, S., Frampton, G. M., Soria, J.-C., Yelensky, R., Commo, F., Brambilla, C., Palmer, G., Moro-Sibilot, D., Ross, J. S., Cronin, M. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7737 · Cited by 175
Ooki, A., Maleki, Z., Tsay, J.-C. J., Goparaju, C., Brait, M., Turaga, N., Nam, H.-S., Rom, W. N., Pass, H. I., Sidransky, D., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1222 · Cited by 175
Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas
Desrichard, A., Kuo, F., Chowell, D., Lee, K.-W., Riaz, N., Wong, R. J., Chan, T. A., & Morris, L. G. T. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy060 · Cited by 176
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2012-09-09
- Volume
- 489
- Issue
- 7417
- Pages
- 519-525
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3466113
- OpenAlex
- W2275877493
- Cited by
- 3,994
- References
- 45
- Citations by year
- 2026: 153 · 2025: 181 · 2024: 189 · 2023: 204 · 2022: 262 · 2021: 296 · 2020: 360 · 2019: 286 · 2018: 329 · 2017: 353 · 2016: 346 · 2015: 371 · 2014: 335 · 2013: 300 · 2012: 24
- FWCI
- 263.50
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-11-07)
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Max Planck Institute for Plasma Physics (submittedVersion)
- eSpace (Curtin University) (submittedVersion, cc-by-nc-sa)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health (5r01ca149569-05)
- BC Cancer Agency
- National Human Genome Research Institute (U54HG003067, HG003067, U54HG003079, HG003079, HG003273, U54HG003273, R01HG006272)
- National Cancer Institute (R01CA094143, U24CA126554, U24CA143882, R01-CA149569, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24CA143845, U24CA126544, R00CA149182, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, T32CA009172, P30CA016672, P30CA016086)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung squamous cell carcinoma, genetic alterations, epigenomic alterations, TP53 mutation, copy number alterations, genome rearrangement, Nrf2, Keap1, PI3K signaling, CDKN2A, RB1, therapeutic target, TCGA
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Squamous Cell, DNA Mutational Analysis, Humans, Lung Neoplasms, Mutation, Signal Transduction, Genome, Human, Gene Expression Regulation, Neoplastic, Genes, p53, Gene Deletion, Phosphatidylinositol 3-Kinases, Genes, p16, Gene Expression Profiling, Genomics, Molecular Targeted Therapy, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.